Floatz logo

Fenretinide

Recurrent Small Lymphocytic Lymphoma

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Recurrent Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Weill Medical College of Cornell University
Phase 2BBB
Fludarabine
Roswell Park Cancer Institute
Phase 3BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB
Cediranib
Mayo Clinic
Phase 2BB
Bortezomib
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Fenretinide is also rated in:

primary peritoneal carcinomaDormant
B
Indicative ·
58 / 100
View asset →
cancerDormant
B
Indicative ·
56 / 100
View asset →
cognitive disorderDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →